Severe Malignant Osteopetrosis Awareness
July 28, 2015
We’ve all heard of osteoporosis – a common disease as we get older that results in bones that are not dense enough. But have you ever heard of severe malignant osteopetrosis? Unless you’re one of only 200 families in the entire country dealing with this devastating diagnosis… you probably haven’t. But severe malignant osteopetrosis is a very rare bone disease. It afflicts babies and young children, its symptoms are devastating, and the financial burden of treatment options weighs heavily on the families it affects. Thanks to physicians like Dr. Paul Orchard, one of the experts in the U.S. in the use of bone marrow stem cell transplants needed by malignant osteopetrosis patients, life expectancy for these young patients is remarkably improved. And thanks to patient advocates like Paul and Barbara Wersten, who fought for the life of their baby Ryan, support organizations like the Ryan Wersten MIOP Foundation are available to patient families. Currently there is also an FDA-approved treatment called ACTIMMUNE® (Interferon Gamma-1b), marketed by Horizon Pharma Inc., helps delay time to disease progression for patients with SMO. Because of these efforts, and ongoing research families dealing with SMO have more hope today.
BioTE Medical is a leader in precision and preventive medicine. They create patient-centric strategies that optimize hormones for women and men.
The Oxford Gold Group was founded on the belief that everyone should have the opportunity to afford and benefit from owning precious metals. They tailor investment strategies for each investor based on their specific needs.
TruSculpt iD and truSculpt flex offer you a total body solution to remove fat, renew skin, and rebuild muscle.